Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a
potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed …

Anidulafungin (LY-303366, V-echinocandin™, Vicuron Pharmaceuticals, Inc.) is a new
echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus …

Anidulafungin is a new echinocandin antifungal agent which inhibits β-1, 3-D-glucan
synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against …

Anidulafungin is the most recently approved compound of the echinocandin antifungal class.
Its mode of action is the noncompetitive inhibition of β–(1, 3)-D-glucan synthesis. Potent …

Anidulafungin (Vicuron Pharmaceuticals) is a new echinocandin antifungal with potent
activity against Aspergillus and Candida spp. Anidulafungin is a noncompetitive inhibitor of …

Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity
against Candida spp., including isolates that are azole and polyene resistant. In addition, it …

Background: Over the past two decades, the frequency and type of invasive fungal infections
have increased greatly and thus have driven the need for new antifungal agents …

This study evaluated the safety and efficacy of anidulafungin, a novel echinocandin, in
patients with invasive candidiasis, including candidemia. A total of 123 eligible patients were …

Importance of the field: Anidulafungin is one of three available intravenous echinocandins
that plays an important role in the treatment of serious fungal infections. Currently …

Until recently, the treatment available for serious fungal infections was composed of
amphotericin B and azoles, and each class demonstrated significant limitations …